UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.04 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 29.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,496 shares of the company’s stock after acquiring an additional 20,166 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Viridian Therapeutics were worth $2,036,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in VRDN. Quest Partners LLC raised its holdings in shares of Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after purchasing an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC increased its position in Viridian Therapeutics by 108.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after purchasing an additional 6,500 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after purchasing an additional 1,688 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter worth about $208,000.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, COO Thomas W. Beetham acquired 5,000 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the purchase, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. This represents a 500.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stephen F. Mahoney bought 21,400 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. This represents a ? increase in their position. The disclosure for this purchase can be found here. 0.65% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on VRDN. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Monday, November 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a report on Thursday, December 5th. BTIG Research lifted their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating for the company. Finally, HC Wainwright raised their price target on Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $36.33.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $17.85 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm’s 50-day moving average is $22.04 and its 200-day moving average is $17.92. Viridian Therapeutics, Inc. has a 52-week low of $11.40 and a 52-week high of $27.20. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -4.14 and a beta of 1.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.